The Mycosis Fungoides drugs in development market research report provides comprehensive information on the therapeutics under development for Mycosis Fungoides, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mycosis Fungoides. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mycosis Fungoides and features dormant and discontinued products.
GlobalData tracks 37 drugs in development for Mycosis Fungoides by 35 companies/universities/institutes. The top development phase for Mycosis Fungoides is phase ii with 18 drugs in that stage. The Mycosis Fungoides pipeline has 35 drugs in development by companies and two by universities/ institutes. Some of the companies in the Mycosis Fungoides pipeline products market are: Bristol-Myers Squibb, CRISPR Therapeutics and SciTech Development.
The key targets in the Mycosis Fungoides pipeline products market include Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, and Tumor Necrosis Factor Receptor Superfamily Member 8.
The key mechanisms of action in the Mycosis Fungoides pipeline product include Programmed Cell Death 1 Ligand 1 Inhibitor with three drugs in Phase II. The Mycosis Fungoides pipeline products include 11 routes of administration with the top ROA being Intravenous and eight key molecule types in the Mycosis Fungoides pipeline products market including Small Molecule, and Monoclonal Antibody.
Mycosis Fungoides overview
Mycosis fungoides is a rare type of non-Hodgkin lymphoma, specifically a subtype of cutaneous T-cell lymphoma (CTCL), which primarily affects the skin. It is characterized by the abnormal accumulation of malignant T-cells (a type of white blood cell) in the skin, leading to various skin symptoms and, in advanced stages, potential involvement of other organs. Mycosis fungoides is the most common type of CTCL, though it remains relatively rare overall. It typically affects adults, with an average age of onset around 55-60 years, though it can occur at any age, including childhood. The disease progresses slowly over years. Initial symptoms may include red, scaly patches on the skin (known as patches or plaques) that may resemble eczema or psoriasis. These lesions are usually itchy but can vary in appearance. Over time, the disease can progress to more defined tumors, ulcers, or nodules on the skin. In advanced cases, lymph nodes and internal organs may become involved. Diagnosis of mycosis fungoides involves a combination of clinical evaluation, skin biopsy, and sometimes additional tests like blood work, imaging studies (X-rays, CT scans, or PET scans), or a lymph node biopsy to determine the extent of the disease.
For a complete picture of Mycosis Fungoides’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
